Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first‐line therapy in advanced nonuterine leiomyosarcoma: A multicenter real‐world study
Makaleler > Tam Makale · 2025
Yazarlar: Salih Tunbekici, Gokhan Sahin, Haydar Cagatay Yuksel, Caner ACAR, Imge Akın, Hasan Aslanhan, Mert Iscı, Ceren Kabaoglu, Hamit Bal, Abdullah Sakin, Alper Coskun, Mehmet Sıddık Dilek, Mahmut Kara, Ali Solmaz, Evrican Zin, Aytac Terzi, Fatih Kus, Ilgın Koc Kus, Zafer Arık, Ali Aytac, Özge Demirkıran, Bilgin Demir, Havva Yesil, Sedat Biter, Tolga Koseci, Ertugrul Bayram, Ahmet Unsal, Alper Sevınc, Duygu Ozaskın, Meltem Baykara, Ahmet Unlu, Arıf Kus, Cengiz Karacin, Galip Can Uyar, Osman Sutcuoglu, Esmanur Kaplan, Teoman Sakalar, Elif Sahin, Gamze Emin, Atilla Yıldırım, Ceren Mordag, Irem Ugurlu, Ilhan Hacıbekiroglu, Ibrahim Tunbekici, Ulus Ali ŞANLI, Erdem GÖKER, Pınar GÜRSOY
International Journal of Cancer, Uluslararası, Wos, 2025, cilt 158, ss 1703-1712
DOI: 10.1002/ijc.70212
Özet
Nonuterine leiomyosarcoma (NU-LMS) is a rare and biologically distinct subtype of soft tissue sarcoma (STS) with clinical behavior differing from that of uterine leiomyosarcoma. In advanced or metastatic STS, immunotherapy has demonstrated only modest activity, and chemotherapy remains the cornerstone of treatment. However, there is a persistent unmet need for more effective and better-tolerated options in this population. This multicenter, retrospective study included 150 patients with histologically confirmed metastatic NU-LMS who received first-line doxorubicin-ifosfamide (AI) or gemcitabine-docetaxel (GD) at 26 oncology centers in Turkey between 2010 and 2024. The primary endpoint was overall survival (OS). Survival was analyzed using Kaplan-Meier estimates and Cox proportional hazards models. Of 150 patients, 79 received AI and 71 received GD. Median OS for the entire cohort was 21.0 months. Median OS was 22.0 months with AI and 19.1 months with GD (p = .18), median progression-free survival was 7.3 versus 6.1 months (p = .66), and overall response rate was 25.3% versus 29.6% (p = .58), indicating no statistically significant differences in efficacy between the two regimens. Hematologic toxicities were less frequent with GD. AI and GD demonstrated comparable efficacy as first-line regimens for advanced or metastatic NU-LMS, with fewer hematologic toxicities observed for GD. Tumor location may have prognostic implications. These findings support individualized treatment selection and highlight the need for prospective studies in this rare and understudied sarcoma subtype, while the recent LMS-04 trial underscores the importance of future comparisons with doxorubicin-trabectedin to further refine first-line strategies in LMS.